

Title (en)  
A PHARMACEUTICAL COMPOSITION COMPRISING PYY AND GLP-1 OR AGONISTS THEREOF AND THE USE THEREOF FOR THE REDUCTION OR PREVENTION OF OBESITY

Title (de)  
PHARMAZEUTISCHES ZUSAMMENSETZUNG ENTHALTEND PYY UND GLP-1 UND ODER DEREN ANTAGONISTEN UND DESSEN VERWENDUNG ZUR REDUZIERUNG ODER VORBEUGUNG VON FETTLLEIBIGKEIT

Title (fr)  
COMPOSITION PHARMACEUTIQUE COMPRENANT DU PYY ET DU GLP-1 ET UTILISATION DE CELLE-SI DANS LA REDUCTION OU LA PREVENTION DE L'OBESITE

Publication  
**EP 1474163 A2 20041110 (EN)**

Application  
**EP 03700848 A 20030110**

Priority

- GB 0300062 W 20030110
- GB 0200507 A 20020110
- US 39210902 P 20020628
- US 0231944 W 20020924

Abstract (en)  
[origin: WO03057235A2] Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering PYY or an agonist thereof and GLP-1 or an agonist thereof to the subject, simultaneously or sequentially, thereby decreasing the calorie intake of the subject.  
[origin: WO03057235A2] Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering PYY or an agonist thereof and GLP-1 or an agonist thereof to the subject, simultaneously or sequentially, thereby decreasing the calorie intake of the subject.

IPC 1-7  
**A61K 38/17; A61K 38/26; A61P 3/04**

IPC 8 full level  
**A61K 38/22** (2006.01); **A61K 45/06** (2006.01); **A61K 38/00** (2006.01); **A61K 38/17** (2006.01); **A61K 38/26** (2006.01); **A61P 3/04** (2006.01); **A61P 3/10** (2006.01)

CPC (source: EP)  
**A61K 38/22** (2013.01); **A61K 38/2278** (2013.01); **A61K 38/26** (2013.01); **A61P 1/04** (2017.12); **A61P 1/16** (2017.12); **A61P 1/18** (2017.12); **A61P 3/04** (2017.12); **A61P 3/06** (2017.12); **A61P 3/10** (2017.12); **A61P 5/00** (2017.12); **A61P 5/24** (2017.12); **A61P 7/02** (2017.12); **A61P 9/00** (2017.12); **A61P 9/04** (2017.12); **A61P 9/10** (2017.12); **A61P 9/12** (2017.12); **A61P 11/00** (2017.12); **A61P 13/12** (2017.12); **A61P 15/00** (2017.12); **A61P 15/08** (2017.12); **A61P 15/14** (2017.12); **A61P 17/02** (2017.12); **A61P 17/04** (2017.12); **A61P 19/00** (2017.12); **A61P 19/02** (2017.12); **A61P 19/06** (2017.12); **A61P 21/00** (2017.12); **A61P 25/00** (2017.12); **A61P 25/02** (2017.12); **A61P 25/06** (2017.12); **A61P 25/08** (2017.12); **A61P 25/14** (2017.12); **A61P 25/22** (2017.12); **A61P 25/24** (2017.12); **A61P 25/28** (2017.12); **A61P 29/00** (2017.12); **A61P 29/02** (2017.12); **A61P 35/00** (2017.12); **A61P 37/02** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)  
See references of WO 03057235A2

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

Designated extension state (EPC)  
AL LT LV MK RO

DOCDB simple family (publication)  
**WO 03057235 A2 20030717; WO 03057235 A3 20031211**; AU 2003201998 A1 20030724; AU 2003201998 B2 20090423; AU 2003201998 C1 20121025; AU 2009203001 A1 20090813; AU 2009203001 A8 20120308; AU 2009203001 B2 20120524; CA 2472882 A1 20030717; EP 1474163 A2 20041110; EP 2329839 A1 20110608; EP 2329839 B1 20150916; JP 2005519059 A 20050630; JP 2009292835 A 20091217; JP 2011052018 A 20110317; JP 4733922 B2 20110727; JP 5226628 B2 20130703

DOCDB simple family (application)  
**GB 0300062 W 20030110**; AU 2003201998 A 20030110; AU 2009203001 A 20090723; CA 2472882 A 20030110; EP 03700848 A 20030110; EP 10186174 A 20030110; JP 2003557592 A 20030110; JP 2009193064 A 20090824; JP 2010275256 A 20101210